RxDoctor Payments Data

Stephen Kyser, PA

Physician Assistant · Toledo, OHNPI 1003113671

Payments from drug & device makers

$4,015in general payments, 2019–2025

Across 82 payments — averaging $48.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$3K
  • Boston Scientific$342
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$272
  • Johnson & Johnson$104
  • Novartis$101
  • Astellas Pharma US Inc$99
  • plus $305 from 8 others

What the payments were for

  • Travel & lodging$1,51838%
  • Food & beverage$2,38459%
  • Education$1133%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,015 in reported general payments places this provider in the 90th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$20,569
Medicare patients
249
Services billed
288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban559$666,377
XareltoRivaroxaban118$134,278
EntrestoSacubitril/Valsartan78$104,877
JardianceEmpagliflozin57$74,233
FarxigaDapagliflozin Propanediol40$43,047
Repatha SureclickEvolocumab50$38,580
Metoprolol Succinate714$13,175
VascepaIcosapent Ethyl22$12,541
Praluent PenAlirocumab13$10,193
Ranolazine ErRanolazine67$9,914
Atorvastatin Calcium749$9,435
Carvedilol508$5,573
Ezetimibe157$5,252
Rosuvastatin Calcium293$5,180
ClopidogrelClopidogrel Bisulfate318$4,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$666,377559 claims
Johnson & JohnsonXarelto$104$134,278118 claims
NovartisEntresto$101$104,87778 claims
AstraZenecaFarxiga$27$43,04740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →